Metasol (Methylprednisolone Hydrogen Succinate)

The drug penetrates cell membranes and binds to intracellular glucocorticoid receptors. This complex moves into the nucleus where it influences gene transcription, increasing anti‑inflammatory proteins and decreasing pro‑inflammatory cytokines. The result is reduced swelling, pain, and immune system activity.

Dosing of Metasol is individualized. The prescribing physician determines the amount, frequency, and route (intramuscular or intravenous) based on the specific indication, severity of disease, patient weight, and response to therapy. Patients should follow the exact regimen provided by their healthcare provider.

The safety of methylprednisolone hydrogen succinate in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers will assess each case and discuss alternatives when appropriate.

To request Metasol, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metasol delivers methylprednisolone hydrogen succinate, which has a rapid onset and high anti‑inflammatory potency compared with some older glucocorticoids like prednisone. Its injectable form allows precise dosing in acute settings, whereas oral formulations may be preferred for chronic management. Choice depends on clinical urgency, route preference, and patient-specific factors.

Metasol should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the vial from moisture, direct sunlight and extreme temperature fluctuations. Do not freeze. Inspect the solution before use; discard if particulate matter or discoloration is observed.

Metasol is supplied as a sterile injectable solution for intramuscular or intravenous administration. The healthcare professional selects the appropriate route, prepares the dose under aseptic conditions, and injects it slowly to minimize discomfort. Administration technique follows standard clinical guidelines for injectable corticosteroids.

Serious risks include adrenal suppression leading to crisis on abrupt discontinuation, severe infections due to immunosuppression, anaphylactic reactions, marked hypertension, psychosis or mood disorders, and osteonecrosis of bone. Patients should be monitored closely for these events, especially during high‑dose or prolonged therapy.

Metasol is contraindicated in patients with known hypersensitivity to methylprednisolone or any formulation component, those with systemic fungal infections, and individuals receiving live vaccines unless the benefits outweigh the risks. Caution is also advised for patients with uncontrolled diabetes, severe hypertension, or active peptic ulcer disease.